Neogenomics Inc (NEO) concluded trading on Wednesday at a closing price of $17.74, with 0.45 million shares of worth about $7.92 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 26.71% during that period and on November 27, 2024 the price saw a gain of about 3.26%. Currently the company’s common shares owned by public are about 127.37M shares, out of which, 126.80M shares are available for trading.
Stock saw a price change of 15.49% in past 5 days and over the past one month there was a price change of 31.21%. Year-to-date (YTD), NEO shares are showing a performance of 9.64% which decreased to -5.89% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.77 but also hit the highest price of $21.22 during that period. The average intraday trading volume for Neogenomics Inc shares is 747.08K. The stock is currently trading 13.35% above its 20-day simple moving average (SMA20), while that difference is up 20.77% for SMA50 and it goes to 18.83% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Neogenomics Inc (NASDAQ: NEO) currently have 127.37M outstanding shares and institutions hold larger chunk of about 97.47% of that.
The stock has a current market capitalization of $2.28B and its 3Y-monthly beta is at 1.23. It has posted earnings per share of -$0.62 in the same period. It has Quick Ratio of 1.91 while making debt-to-equity ratio of 0.67. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NEO, volatility over the week remained 4.17% while standing at 4.35% over the month.
Stock’s fiscal year EPS is expected to rise by 180.95% while it is estimated to increase by 102.21% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on May 01, 2024 offering a Buy rating for the stock and assigned a target price of $26 to it. Coverage by BTIG Research stated Neogenomics Inc (NEO) stock as a Buy in their note to investors on December 29, 2023, suggesting a price target of $21 for the stock. Stock get a Buy rating from BTIG Research on May 09, 2023.
